UK rolls out new drug approval pathway
Effective 1 January 2022 Pharmaceutical companies can now seek accelerated drug approvals in the UK using the newly launched Innovative Licensing and Access Pathway (ILAP). The new approval… read more.
Effective 1 January 2022 Pharmaceutical companies can now seek accelerated drug approvals in the UK using the newly launched Innovative Licensing and Access Pathway (ILAP). The new approval… read more.
Long-term paracetamol use could increase the risk of heart disease and strokes in people with high blood pressure, a study suggests. Patients who have a long-term prescription for… read more.
Obesity is known to cause cardiometabolic diseases like hypertension and diabetes but attributing these diseases to merely an overabundance of fat is a simplification. On a basic level,… read more.
Pregnant women with COVID-19 appear to be at greater risk for common pregnancy complications — in addition to health risks from the virus — than pregnant women without… read more.
An international consortium of leading migraine scientists identified more than 120 regions of the genome that are connected to risk of migraine. The groundbreaking study helps researchers better… read more.
A discovery that blocks the normal transition of semen from a thick gel to a liquid shows promise for development of a new form of non-hormonal, over-the-counter contraception…. read more.
ViiV Healthcare presented positive interim data from the Phase III CARISEL study of Vocabria + Rekambys (cabotegravir + rilpivirine), which was initiated and conducted during the COVID-19 pandemic…. read more.
Trametinib, a drug treatment for skin and lung cancers, appears to slow the progression of low-grade serous cancer of the ovary and to increase the number of patients… read more.
Genentech/Roche presented new data from the Phase III IMpower010 study at the European Society for Medical Oncology (ESMO) Congress 2021 Presidential Symposium, reinforcing the significant disease-free survival (DFS)… read more.
With low rates of disease flare and reactogenicity after vaccination, the study findings are reassuring for both patients and clinicians, according to Dr Caoilfhionn Connolly, Rheumatology Fellow at… read more.
More and more evidence is coming out that people with COVID-19 are suffering from cognitive effects, such as brain fog and fatigue. And researchers are discovering why. The… read more.
NICE (UK)-Palforzia from Aimmune/Nestle is recommended, within its marketing authorisation, as an option for treating peanut allergy in children aged 4 to 17. It can be continued in… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.